The KressWorks Foundation and Rosa Complete Phase 1 of Ewing’s Sarcoma PhysioPD(TM) Research Platform
SAN CARLOS, Calif., March 28, 2014 /PRNewswire/ — Rosa & Co. LLC and the KressWorks Foundation are pleased to announce the completion of the Ewing’s sarcoma PhysioMap®. Completion of the PhysioMap is the first milestone in the development of the Ewing’s sarcoma PhysioPD Platform. The Ewing’s sarcoma PhysioMap was created to provide a formalized, graphical representation of key biological systems and processes underlying Ewing’s sarcoma disease progression and associated therapeutic interventions. The PhysioMap contains the Hallmarks of Cancer, cancer-promoting processes, such as sustained proliferative signaling and resistance to cell death which integrate signals from biological pathways, controlling the growth, proliferation, and metastatic potential of the cancer cells.
When the Ewing’s sarcoma PhysioMap is converted into a PhysioPD Platform, it will be used to understand the signaling pathways contributing to disease progression and investigate the mechanisms underlying the response to standard-of-care chemotherapeutic regimens. The KressWorks Foundation plans to incorporate the PhysioPD Platform into a Systematic Treatment Methodology that will combine computational models with clinical measurements to provide optimized treatment regimens for individual cancer patients.
Rosa helps clients with their critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of R&D related challenges, Rosa offers customized approaches: classic pharmacokinetic/pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD(TM) models. With these capabilities, Rosa’s clients participate in customized model creation, testing, and research simulations, retain the models, and acquire the ability to perform model research to inform decisions and better understand implications for their drug development programs. Rosa’s staff has unparalleled professional experience in applying modeling and simulation to accelerate drug development and have completed hundreds of engagements with clients in virtually all therapeutic areas, including metabolic diseases, oncology, inflammation, immune dysfunction, CNS, dermatology, and antibacterial/antiviral biology. For more information, visit www.rosaandco.com.
The KressWorks Foundation is a nonprofit, 501(c) (3) Scientific and Engineering research corporation that researches, develops, and applies practical, effective technologies and methodologies to the improvement of the Human Condition. Its primary focus is to deliver an effective and systematic methodology that provides optimal treatment regimens for patients suffering from Ewing’s Sarcoma and is extensible to other forms of cancer and other diseases.
This work is funded, in part, by a generous $20,000 donation by Mobility Transportation Services of Canton, MI (http://www.mobilitytrans.com/about_us/index.php).
For more information, visit http://www.kressworks.org.
Read more news from Rosa & Co.
SOURCE Rosa & Co.